Quick Answer
Sarepta Therapeutics, Inc. reported Operating Income Loss of -$699.78 million for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -420.9% in Operating Income Loss from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$25.12 million | Q2 2014: -$30.27 million | Q3 2014: -$33.68 million | Q4 2014: -$44.72 million | Q1 2015: -$61.86 million | Q2 2015: -$42.11 million | Q3 2015: -$51.76 million | Q4 2015: -$64.45 million | Q1 2016: -$59.70 million | Q2 2016: -$62.10 million | Q3 2016: -$56.53 million | Q4 2016: -$88.40 million | Q1 2017: -$39.25 million | Q2 2017: -$63.34 million | Q3 2017: -$45.91 million | Q4 2017: -$23.15 million | Q1 2018: -$30.74 million | Q2 2018: -$103.43 million | Q3 2018: -$70.10 million | Q4 2018: -$139.36 million | Q1 2019: -$76.39 million | Q2 2019: -$275.37 million | Q3 2019: -$123.59 million | Q4 2019: -$230.22 million | Q1 2020: -$118.03 million | Q2 2020: -$138.35 million | Q3 2020: -$137.07 million | Q4 2020: -$170.72 million | Q1 2021: -$151.87 million | Q2 2021: -$167.57 million | Q3 2021: -$34.46 million | Q1 2022: -$86.88 million | Q2 2022: -$211.13 million | Q3 2022: -$131.36 million | Q1 2023: -$138.09 million | Q2 2023: -$133.52 million | Q3 2023: -$20.84 million | Q1 2024: $34.91 million | Q2 2024: -$701.0 thousand | Q3 2024: $22.20 million | Q1 2025: -$300.39 million | Q2 2025: $115.58 million | Q3 2025: -$103.39 million.
- Over the full 17 years of available data (2009 to 2025), Sarepta Therapeutics, Inc.'s Operating Income Loss has declined by 4,412.7%.
- Historical annual values: Fiscal year 2025: -$699.78 million | Fiscal year 2024: $218.08 million | Fiscal year 2023: -$267.82 million | Fiscal year 2022: -$536.20 million | Fiscal year 2021: -$459.71 million | Fiscal year 2020: -$564.16 million | Fiscal year 2019: -$705.56 million | Fiscal year 2018: -$343.63 million | Fiscal year 2017: -$171.64 million | Fiscal year 2016: -$266.73 million | Fiscal year 2015: -$220.18 million | Fiscal year 2014: -$133.79 million | Fiscal year 2013: -$90.28 million | Fiscal year 2012: -$29.70 million | Fiscal year 2011: -$35.93 million | Fiscal year 2010: -$20.93 million | Fiscal year 2009: -$15.51 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: